NeoPhore

Cancer cells
#Funding #Immunotherpy #NeoPhore #Proteins #Small molecules

Financing extension for neoantigen immuno-oncology company 

NeoPhore has announced a further extension of £9.6 million (approximately $12.2 million) to its Series B financing round, bringing the total raised to £31.1 million (approximately $39.5 million).  The company is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (MMR)… Read More

#Business & Investment #Cancer Research #News

Human breast cancer cells stained for DNA
#Cancer research #Collaboration #DNA #NeoPhore #Oncology #Partnership #The Institute of Cancer Research

Immuno-oncology collaboration to develop new type of cancer drug

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Under a new strategic research collaboration, an ICR team led by Professor Chris Lord will investigate the effect of NeoPhore’s inhibitors on… Read More

#Business & Investment #News